Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?

• Immune checkpoint inhibitors are approved for all mismatch repair deficient tumors. • Although rare, autoimmune myositis complicating pembrolizumab therapy may be fatal. • In this case, pembrolizumab caused rhabdomyolysis but also a durable response. • Severe autoimmune reaction may be associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Khetan, Varun, Blake, Erin A., Ciccone, Marcia A., Matsuo, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815810/
https://www.ncbi.nlm.nih.gov/pubmed/33511262
http://dx.doi.org/10.1016/j.gore.2021.100700
_version_ 1783638311872495616
author Khetan, Varun
Blake, Erin A.
Ciccone, Marcia A.
Matsuo, Koji
author_facet Khetan, Varun
Blake, Erin A.
Ciccone, Marcia A.
Matsuo, Koji
author_sort Khetan, Varun
collection PubMed
description • Immune checkpoint inhibitors are approved for all mismatch repair deficient tumors. • Although rare, autoimmune myositis complicating pembrolizumab therapy may be fatal. • In this case, pembrolizumab caused rhabdomyolysis but also a durable response. • Severe autoimmune reaction may be associated with durable treatment response.
format Online
Article
Text
id pubmed-7815810
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78158102021-01-27 Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response? Khetan, Varun Blake, Erin A. Ciccone, Marcia A. Matsuo, Koji Gynecol Oncol Rep Case Report • Immune checkpoint inhibitors are approved for all mismatch repair deficient tumors. • Although rare, autoimmune myositis complicating pembrolizumab therapy may be fatal. • In this case, pembrolizumab caused rhabdomyolysis but also a durable response. • Severe autoimmune reaction may be associated with durable treatment response. Elsevier 2021-01-11 /pmc/articles/PMC7815810/ /pubmed/33511262 http://dx.doi.org/10.1016/j.gore.2021.100700 Text en © 2021 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Khetan, Varun
Blake, Erin A.
Ciccone, Marcia A.
Matsuo, Koji
Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
title Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
title_full Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
title_fullStr Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
title_full_unstemmed Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
title_short Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
title_sort rhabdomyolysis following single administration of pembrolizumab: is severe immune-reaction a marker for durable treatment response?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815810/
https://www.ncbi.nlm.nih.gov/pubmed/33511262
http://dx.doi.org/10.1016/j.gore.2021.100700
work_keys_str_mv AT khetanvarun rhabdomyolysisfollowingsingleadministrationofpembrolizumabissevereimmunereactionamarkerfordurabletreatmentresponse
AT blakeerina rhabdomyolysisfollowingsingleadministrationofpembrolizumabissevereimmunereactionamarkerfordurabletreatmentresponse
AT cicconemarciaa rhabdomyolysisfollowingsingleadministrationofpembrolizumabissevereimmunereactionamarkerfordurabletreatmentresponse
AT matsuokoji rhabdomyolysisfollowingsingleadministrationofpembrolizumabissevereimmunereactionamarkerfordurabletreatmentresponse

Ejemplares similares